TY - JOUR
T1 - Accelerating access for all through research and innovation in immunization
T2 - Recommendations from Strategic Priority 7 of the Immunization Agenda 2030
AU - Sarley, David
AU - Hwang, Angela
AU - Fenton Hall, B.
AU - Ford, Andrew
AU - Giersing, Birgitte
AU - Kaslow, David C.
AU - Wahl, Brian
AU - Friede, Martin
N1 - Funding Information:
The authors thank the contributors to the IA2030 SP7 Technical Working Group, and all the stakeholders who provided guidance and feedback on the Research and Innovation in the next decade. This work was supported in part by the Bill & Melinda Gates Foundation, Seattle, WA (grant INV-003658 to WHO).
Publisher Copyright:
© 2022
PY - 2022
Y1 - 2022
N2 - Research and innovation have been fundamental to many of the successes in immunization thus far, and will play important roles in the future success of Immunization Agenda 2030 (IA2030). Strategic Priority 7 (SP7) of IA2030, which addresses research and innovation, is explicitly informed by country needs and priorities, and aims to strengthen the innovation ecosystem through capacity building and collaboration at country, regional, and global levels. SP7 identifies four key focus areas: (1) “needs-based innovation”, (2) “new and improved products, services, and practices”, (3) “evidence for implementation”, and (4) “local capacity”. Strategic interventions in these key focus areas apply the lessons of the Global Vaccine Action Plan and the “Decade of Vaccines” to emphasize local innovation, promote the use of research by countries to improve program performance and impact, and encourage capacity building for the development and implementation of innovations. The proposed approach will maintain a focus on the development of new vaccines and the improvement of existing vaccines, and increase attention to innovation in service delivery. Monitoring and evaluation will foster evidence-based priority setting at the country level and help to ground the global research and development (R&D) agenda in the needs of communities. Together, these approaches are intended to harness the power of research and innovation more effectively, to meet the challenges of the future and achieve the ambitious goals of IA2030.
AB - Research and innovation have been fundamental to many of the successes in immunization thus far, and will play important roles in the future success of Immunization Agenda 2030 (IA2030). Strategic Priority 7 (SP7) of IA2030, which addresses research and innovation, is explicitly informed by country needs and priorities, and aims to strengthen the innovation ecosystem through capacity building and collaboration at country, regional, and global levels. SP7 identifies four key focus areas: (1) “needs-based innovation”, (2) “new and improved products, services, and practices”, (3) “evidence for implementation”, and (4) “local capacity”. Strategic interventions in these key focus areas apply the lessons of the Global Vaccine Action Plan and the “Decade of Vaccines” to emphasize local innovation, promote the use of research by countries to improve program performance and impact, and encourage capacity building for the development and implementation of innovations. The proposed approach will maintain a focus on the development of new vaccines and the improvement of existing vaccines, and increase attention to innovation in service delivery. Monitoring and evaluation will foster evidence-based priority setting at the country level and help to ground the global research and development (R&D) agenda in the needs of communities. Together, these approaches are intended to harness the power of research and innovation more effectively, to meet the challenges of the future and achieve the ambitious goals of IA2030.
KW - IA2030
KW - Innovation
KW - Research
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=85144364495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144364495&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2022.11.041
DO - 10.1016/j.vaccine.2022.11.041
M3 - Article
C2 - 36529593
AN - SCOPUS:85144364495
SN - 0264-410X
JO - Vaccine
JF - Vaccine
ER -